icon-folder.gif   Conference Reports for NATAP  
 
  66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015
Back grey_arrow_rt.gif
 
 
 
No Pharmacokinetic Interaction Between HCV NS5A Inhibitor Elbasvir and Buprenorphine/Naloxone in Healthy Volunteers - C-EDGE C-Star Study: Grazoprevir/Elbasvir in IDUs on Opioid Antagonist Therapy
 
 
  Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
 
William L. Marshall1; Ted Marenco2; Hwa-Ping Feng1; April M. Barbour1; Jocelyn Gilmartin1; Fang Liu1; Deborah Panebianco1; Angela Mirzac2; Mike Di Spirito2; Daria Stypinski2; Ziv Machnes2; Michael Gartner2; Marian Iwamoto1; Joan R. Butterton1; Wendy W. Yeh1
1Merck & Co., Inc., Kenilworth, NJ, USA; 2Celerion, Lincoln, NE, USA
 
AASLD: C-EDGE CO-STAR: efficacy of grazoprevir / elbasvir Fixed Dose Combination for 12 Weeks in HCV-infected Persons Who Inject Drugs on Opioid Agonist Therapy - (11/16/15)
 
AASLD: Eliminate Restrictions to Substance Users/Injection Drug Users - SVR Rates the Same in New Study as in Non-IDUs 96% - Routine HCV Testing is needed - (11/18/15)
 
AASLD: Merck at AASLD / HepDart 2015 - (01/14/16)
 

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif

AASLD13.gif

AASLD14.gif